Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeyanthy Eswaran

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|June 29, 2011
Atypical GTPases as drug targetsMeera Soundararajan, Jeyanthy Eswaran
Biochimica Et Biophysica Acta|October 27, 2009
Insights into protein kinase regulation and inhibition by large scale structural comparisonJeyanthy Eswaran, Stefan Knapp
Journal of Molecular Biology|March 12, 2003
Locking TolC entrance helices to prevent protein translocation by the bacterial type I export apparatusJeyanthy Eswaran, Colin Hughes, Vassilis Koronakis
Annual Review of Biochemistry|June 11, 2004
Structure and function of TolC: the bacterial exit duct for proteins and drugsVassilis Koronakis, Jeyanthy Eswaran, Colin Hughes
Cancer Metastasis Reviews|January 23, 2009
Targeting group II PAKs in cancer and metastasisJeyanthy Eswaran, Meera Soundararajan, Stefan Knapp
Trends in Biochemical Sciences|July 22, 2008
UnPAKing the class differences among p21-activated kinasesJeyanthy Eswaran, Meera Soundararajan, Rakesh Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2012
Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitationsJeyanthy Eswaran, Da-Qiang Li, Anil Shah, et al.
Plos One|March 3, 2011
Gene profiling of MTA1 identifies novel gene targets and functionsKrishna Sumanth Ghanta, Da-Qiang Li, Jeyanthy Eswaran, et al.
Structure (London, England : 1993)|January 15, 2009
Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding siteEric D Scheeff, Jeyanthy Eswaran, Gabor Bunkoczi, et al.
Current Opinion in Structural Biology|December 8, 2004
Three's company: component structures bring a closer view of tripartite drug efflux pumpsJeyanthy Eswaran, Eva Koronakis, Matthew K Higgins, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Anti-Cancer Agents in Medicinal Chemistry|June 29, 2011
Atypical GTPases as drug targetsMeera Soundararajan, Jeyanthy Eswaran
Biochimica Et Biophysica Acta|October 27, 2009
Insights into protein kinase regulation and inhibition by large scale structural comparisonJeyanthy Eswaran, Stefan Knapp
Journal of Molecular Biology|March 12, 2003
Locking TolC entrance helices to prevent protein translocation by the bacterial type I export apparatusJeyanthy Eswaran, Colin Hughes, Vassilis Koronakis
Annual Review of Biochemistry|June 11, 2004
Structure and function of TolC: the bacterial exit duct for proteins and drugsVassilis Koronakis, Jeyanthy Eswaran, Colin Hughes
Cancer Metastasis Reviews|January 23, 2009
Targeting group II PAKs in cancer and metastasisJeyanthy Eswaran, Meera Soundararajan, Stefan Knapp
Trends in Biochemical Sciences|July 22, 2008
UnPAKing the class differences among p21-activated kinasesJeyanthy Eswaran, Meera Soundararajan, Rakesh Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2012
Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitationsJeyanthy Eswaran, Da-Qiang Li, Anil Shah, et al.
Plos One|March 3, 2011
Gene profiling of MTA1 identifies novel gene targets and functionsKrishna Sumanth Ghanta, Da-Qiang Li, Jeyanthy Eswaran, et al.
Structure (London, England : 1993)|January 15, 2009
Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding siteEric D Scheeff, Jeyanthy Eswaran, Gabor Bunkoczi, et al.
Current Opinion in Structural Biology|December 8, 2004
Three's company: component structures bring a closer view of tripartite drug efflux pumpsJeyanthy Eswaran, Eva Koronakis, Matthew K Higgins, et al.
Pageof 4